Eli Lilly  Shares Outstanding History
Below is a table of the Eli Lilly shares outstanding history going back to 2/12/2010:

Date LLY Shares Outstanding
2/12/20101.15B
4/20/20101.15B
7/20/20101.15B
10/20/20101.15B
2/15/20111.16B
4/20/20111.16B
7/20/20111.16B
10/20/20111.16B
2/15/20121.16B
4/20/20121.16B
7/20/20121.16B
10/20/20121.16B
2/15/20131.13B
4/30/20131.13B
7/20/20131.13B
10/23/20131.13B
2/14/20141.12B
4/21/20141.12B
7/21/20141.12B
10/20/20141.11B
2/13/20151.11B
4/20/20151.11B
7/20/20151.11B
10/19/20151.11B
4/18/20161.10B
7/18/20161.10B
10/17/20161.10B
2/13/20171.10B
4/24/20171.10B
7/17/20171.10B
10/23/20171.10B
2/14/20181.10B
4/23/20181.09B
7/23/20181.07B
11/2/20181.06B
2/13/20191.04B
4/29/2019970.83M
7/29/2019965.43M
10/21/2019960.13M
2/13/2020956.38M

Also see: LLY Market Cap History
LLY YTD Return
LLY RSI
LLY DMA
LLY MACD
LLY Technical Analysis
Eli Lilly Historical Shares Outstanding:
-1.85% CAGR
Eli Lilly  Historical Shares Outstanding: +-1.85% CAGR

Mouse over chart for data details
2/12/2010 ...2/13/2020
Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s human pharmaceutical products include: diabetes and other endocrinology products, immunology products, neuroscience products, oncology products, and other products. Co.'s diabetes and other endocrinology products include: Baqsimi® and Basaglar®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta® and Emgality®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux® and Verzenio®. Co.'s other products include: Cialis®. We show 40 historical shares outstanding datapoints in our coverage of LLY's shares outstanding history.

Understanding the changing numbers of Eli Lilly shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like Eli Lilly versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching Eli Lilly by allowing them to research Eli Lilly shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes
Get Free SEC filing alerts for LLY:
LLY SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Eli Lilly (LLY) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

LMAT Shares Outstanding History
LMNX Shares Outstanding History
LNTH Shares Outstanding History
LOXO Shares Outstanding History
LPCN Shares Outstanding History
LPNT Shares Outstanding History
LPTX Shares Outstanding History
LXRX Shares Outstanding History
MACK Shares Outstanding History
MASI Shares Outstanding History
More Healthcare companies »

 

Eli Lilly Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2020, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.